Literature DB >> 9392980

Intramuscular high-dose triamcinolone acetonide in the treatment of severe chronic asthma.

L Mancinelli1, L Navarro, O P Sharma.   

Abstract

We describe our experience with administering intramuscular triamcinolone acetonide to 22 steroid-dependent patients with asthma. These patients represent the minority of those with asthma whose disease is characterized by frequent emergency department visits, hospital admissions, and long-term dependency on oral corticosteroid therapy. The participants were randomly assigned to 2 treatment groups, one group receiving 120 mg of intramuscular triamcinolone acetonide, the second receiving 360 mg as a series of three 120-mg daily doses. We determined relative efficacy by comparing peak expiratory flow rates and incidents of emergency department visits, hospital admissions, and ventilatory failure of the study and during the 12 months before enrollment. Peak expiratory flow rates improved significantly in both groups. The mean (+/- standard deviation [SD]) monthly percentage of predicted peak expiratory flow on the study was 88.6 +/- 3.7% and 91.2 +/- 3.9% compared with 63 +/- 15.1% and 64 +/- 14.5% at entry in patients receiving 120 and 360 mg, respectively (P < 0.02). Patients receiving 120 mg required 8 hospital stays and 8 emergency department visits compared with 27 hospital stays and 72 emergency department visits in the previous year (P < 0.05). Patients receiving 360 mg required 5 hospital stays and 5 emergency department visits compared with 33 hospital stays and 34 emergency department visits in the previous year (P < 0.05). The average monthly interval (+/- SD) between exacerbations was 2.7 +/- 2.3 and 7.8 +/- 3.5 for patients receiving 120 mg and 360 mg, respectively. A total of 25 intubations was required in the previous year and only 1 during the study. The incidence of cushingoid facies, weight gain, and hypertension was reduced in both groups (P < 0.05). Total steroid use was reduced in both groups (P < 0.02). A dose of 360 mg produced a longer exacerbation-free period than 120 mg (P < 0.02).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9392980      PMCID: PMC1304618     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  15 in total

1.  Chrysotherapy in the treatment of corticosteroid-dependent asthma.

Authors:  W B Klaustermeyer; D T Noritake; F K Kwong
Journal:  J Allergy Clin Immunol       Date:  1987-05       Impact factor: 10.793

2.  Effect of long-acting parenteral corticosteroids on adrenal function.

Authors:  G R Mikhail; C S Livingood; R C Mellinger; T N Paige; H L Salyer
Journal:  Arch Dermatol       Date:  1969-09

3.  Intramuscular triamcinolone acetonide in chronic severe asthma.

Authors:  D T McLeod; S J Capewell; J Law; W MacLaren; A Seaton
Journal:  Thorax       Date:  1985-11       Impact factor: 9.139

4.  Comparison of oral prednisolone and intramuscular depot triamcinolone in patients with severe chronic asthma.

Authors:  R F Willey; R J Fergusson; D J Godden; G K Crompton; I W Grant
Journal:  Thorax       Date:  1984-05       Impact factor: 9.139

5.  Increases in deaths from asthma.

Authors:  R M Sly
Journal:  Ann Allergy       Date:  1984-07

6.  Methotrexate in the treatment of corticosteroid-dependent asthma. A double-blind crossover study.

Authors:  M F Mullarkey; B A Blumenstein; W P Andrade; G A Bailey; I Olason; C E Wetzel
Journal:  N Engl J Med       Date:  1988-03-10       Impact factor: 91.245

7.  National trends in the morbidity and mortality of asthma in the US. Prevalence, hospitalization and death from asthma over two decades: 1965-1984.

Authors:  R Evans; D I Mullally; R W Wilson; P J Gergen; H M Rosenberg; J S Grauman; F M Chevarley; M Feinleib
Journal:  Chest       Date:  1987-06       Impact factor: 9.410

8.  Triamcinolone in corticosteroid-resistant asthma.

Authors:  M D Peake; R M Cayton; P Howard
Journal:  Br J Dis Chest       Date:  1979-01

9.  An improved protocol for the use of troleandomycin (TAO) in the treatment of steroid-requiring asthma.

Authors:  J A Wald; B F Friedman; R S Farr
Journal:  J Allergy Clin Immunol       Date:  1986-07       Impact factor: 10.793

10.  Gold salt in the treatment of bronchial asthma--a double-blind study.

Authors:  M Muranaka; T Miyamoto; T Shida; J Kabe; S Makino; H Okumura; K Takeda; S Suzuki; Y Horiuchi
Journal:  Ann Allergy       Date:  1978-02
View more
  1 in total

1.  Triamcinolone acetonide: a new management of noncompliance in nephrotic children.

Authors:  Tim Ulinski; Anne Carlier-Legris; Déborah Schlecht; Bruno Ranchin; Pierre Cochat
Journal:  Pediatr Nephrol       Date:  2005-04-21       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.